Can You Take Repatha (Evolocumab) With Apixaban?

Why These Two Drugs Are Frequently Co-Prescribed

Patients with established atherosclerotic cardiovascular disease (ASCVD) often carry a simultaneous diagnosis of atrial fibrillation (AF). About 25% of AF patients also meet criteria for high-intensity lipid-lowering therapy according to the 2018 AHA/ACC Cholesterol Guideline [1]. That overlap means a growing number of patients take a PCSK9 inhibitor like evolocumab alongside a direct oral anticoagulant (DOAC) like apixaban.

The Clinical Scenario

Evolocumab is FDA-approved for heterozygous familial hypercholesterolemia (HeFH), homozygous FH (HoFH), and established ASCVD requiring additional LDL-C lowering beyond maximally tolerated statin therapy [2]. Apixaban is FDA-approved for stroke prevention in non-valvular AF and for treatment/prevention of venous thromboembolism [3]. A patient with AF who also has ASCVD and an LDL-C that remains above goal on a statin may need both drugs simultaneously.

Why the Question Matters

Apixaban has a narrow therapeutic window. Drugs that inhibit its CYP3A4 or P-gp clearance pathways can raise plasma levels and increase bleeding risk. Strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir) require a 50% apixaban dose reduction per the FDA-approved Eliquis label [3]. Patients and prescribers reasonably ask whether adding a second injectable biologic could create a similar problem.

Pharmacokinetic Profiles: No Overlapping Metabolism

Evolocumab and apixaban are eliminated through entirely separate biological systems. This separation is the primary reason no pharmacokinetic interaction is expected.

Evolocumab: Monoclonal Antibody Clearance

Evolocumab is a fully human IgG2 monoclonal antibody. Like all therapeutic monoclonal antibodies, it is degraded by intracellular proteolysis into small peptides and amino acids via the reticuloendothelial system [4]. It does not undergo hepatic cytochrome P450 metabolism. It is not a substrate, inhibitor, or inducer of any CYP enzyme or drug transporter. The Repatha prescribing information contains no drug interaction section listing specific contraindicated or cautionary co-medications [2].

Apixaban: CYP3A4 and P-gp Dependent

Apixaban is a small-molecule Factor Xa inhibitor metabolized primarily by CYP3A4, with minor contributions from CYP1A2, CYP2C8, CYP2C19, and CYP2J2. It is also a substrate of the P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) efflux transporters [3]. Clinically significant interactions occur when strong dual CYP3A4/P-gp inhibitors or inducers change apixaban exposure by more than twofold.

The Bottom Line on Overlap

Because evolocumab never enters the CYP or transporter system, it cannot alter apixaban clearance. A 2019 review in Clinical Pharmacology & Therapeutics confirmed that monoclonal antibodies as a drug class lack CYP-mediated interactions, with the exception of antibodies that modulate cytokine signaling (e.g., tocilizumab affecting IL-6-driven CYP3A4 suppression) [5]. Evolocumab targets PCSK9, a protein with no known role in CYP regulation.

What the FOURIER Trial Tells Us About Co-Administration

The FOURIER trial (N=27,564) randomized patients with established ASCVD to evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo on top of statin therapy [6]. The trial did not exclude patients on anticoagulants.

Bleeding Signal in FOURIER

In FOURIER, the rate of hemorrhagic stroke was 0.2% in the evolocumab group versus 0.2% in the placebo group over a median 2.2 years of follow-up [6]. No excess bleeding of any type was attributed to evolocumab. A prespecified safety analysis published in the New England Journal of Medicine found no increase in serious adverse events including hemorrhagic events even at LDL-C levels below 20 mg/dL [7].

Subgroup Data on Antithrombotic Use

Approximately 15.6% of FOURIER participants were on oral anticoagulants at baseline, and over 93% were on at least one antiplatelet agent [6]. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) regardless of baseline antithrombotic regimen. No interaction between evolocumab efficacy or safety and anticoagulant use was detected.

Pharmacodynamic Considerations

While the pharmacokinetic interaction risk is negligible, clinicians should consider indirect pharmacodynamic effects that may be relevant when these drugs are used together.

LDL-C Reduction and Hemostasis

Very low LDL-C has raised theoretical concerns about hemorrhagic stroke risk based on observational epidemiology. A 2019 meta-analysis in Neurology (N=248,391 across 23 studies) found a modest association between LDL-C below 70 mg/dL and hemorrhagic stroke (RR 1.10, 95% CI 1.02 to 1.19) [8]. The absolute risk increase was small: roughly 0.3 additional hemorrhagic strokes per 1,000 patient-years.

Clinical Relevance for Apixaban Users

For patients already on an anticoagulant, the combination of very low LDL-C plus anticoagulation could, in theory, compound a small hemorrhagic stroke risk. In practice, the FOURIER data showed no such signal, and the 2022 EAS Consensus Statement noted that the cardiovascular benefit of achieving LDL-C targets far outweighs this theoretical concern for most ASCVD patients [9].

Dr. Marc Sabatine, lead FOURIER investigator, stated in a 2020 JACC editorial: "The totality of randomized trial evidence does not support withholding LDL-lowering therapy out of concern for hemorrhagic stroke" [10].

Platelet Function

Evolocumab does not affect platelet aggregation, coagulation factor activity, or thrombin generation. A dedicated platelet-function substudy within FOURIER confirmed no change in platelet reactivity with PCSK9 inhibition [11]. This distinguishes PCSK9 inhibitors from other lipid-lowering agents (e.g., omega-3 fatty acids at high doses) that may have mild antithrombotic properties.

Monitoring Recommendations When Using Both Drugs

No special monitoring is required solely because of co-administration. Standard monitoring for each drug individually applies.

For Evolocumab

• Fasting lipid panel 4 to 12 weeks after initiation and periodically thereafter per the ACC/AHA guideline [1]
• Liver function is not required by the Repatha label, but clinicians commonly check hepatic transaminases given concomitant statin use
• Injection-site reactions (3.2% in FOURIER vs. 3.0% placebo) should be assessed at follow-up visits [6]

For Apixaban

• Renal function (serum creatinine, eGFR) at baseline and at least annually, since apixaban dose reduction to 2.5 mg twice daily is recommended when two of three criteria are met: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [3]
• CBC to monitor for occult bleeding
• Anti-factor Xa level if there is clinical suspicion of accumulation or subtherapeutic dosing (not routine)

When to Reassess

A practical trigger for reassessment is any change in renal function, hepatic function, or the addition of a new drug that is a strong CYP3A4/P-gp inhibitor or inducer. Examples include starting clarithromycin, itraconazole, rifampin, or certain HIV protease inhibitors. Evolocumab itself does not create this trigger.

Dose Adjustment Guidance

No dose adjustment of either drug is needed based on co-administration alone.

Evolocumab Dosing Remains Standard

The approved dose is 140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly [2]. Neither dose requires modification based on anticoagulant use.

Apixaban Dosing Follows Its Own Criteria

Apixaban 5 mg twice daily is standard for AF patients. The reduced dose of 2.5 mg twice daily applies per the criteria above (age, weight, creatinine), and VTE treatment uses 10 mg twice daily for 7 days followed by 5 mg twice daily [3]. None of these dose decisions are influenced by evolocumab.

Other Repatha Drug Interactions to Be Aware Of

While evolocumab has no known clinically significant drug-drug interactions, patients taking it often use multiple cardiovascular medications. A brief overview of interactions relevant to common co-prescribed drugs helps put the apixaban question in context.

Statins

Evolocumab is designed to be used with statins. No pharmacokinetic interaction exists. In FOURIER, 69.3% of patients were on high-intensity statin therapy [6]. Myalgia rates did not differ between evolocumab and placebo arms.

Other Anticoagulants and Antiplatelets

The same lack of CYP/P-gp involvement means evolocumab does not interact with warfarin, rivaroxaban, dabigatran, edoxaban, aspirin, or clopidogrel. The ODYSSEY OUTCOMES trial of alirocumab (a different PCSK9 inhibitor with the same monoclonal antibody clearance mechanism) similarly showed no excess bleeding in patients on dual antiplatelet therapy [12].

Drugs That Do Interact With Apixaban

Patients and clinicians should remain vigilant about drugs that genuinely affect apixaban levels. Per the Eliquis prescribing information [3]:

• Strong dual CYP3A4/P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin): reduce apixaban dose by 50%
• Strong dual CYP3A4/P-gp inducers (rifampin, carbamazepine, phenytoin, St. John's wort): avoid co-administration
• Combined P-gp and moderate CYP3A4 inhibitors (diltiazem, naproxen, amiodarone): generally no dose change, but clinical awareness is warranted

Patient Counseling Points

Patients prescribed both Repatha and Eliquis benefit from a few targeted talking points.

What to Tell Patients

1. These two medications work through completely independent pathways. Taking them together does not increase the blood-thinning effect of apixaban.
2. Continue to report any unusual bruising, prolonged bleeding from cuts, blood in urine or stool, or severe headaches. These are standard apixaban precautions, not specific to the combination.
3. Injection-site reactions from Repatha (redness, pain, bruising at the injection site) are not related to anticoagulation status.

Timing of Administration

No specific timing separation is required. Evolocumab is administered every 2 weeks or monthly by subcutaneous injection, and apixaban is taken orally twice daily. Patients can administer the Repatha injection at any time relative to their apixaban doses.

The 2019 Endocrine Society Clinical Practice Guideline on lipid management does not include any timing restrictions for PCSK9 inhibitors relative to other medications [13].

Summary of Evidence by Interaction Type

| Interaction type | Risk level | Mechanism | Clinical action | |---|---|---|---| | Pharmacokinetic (CYP3A4) | None | Evolocumab is not a CYP substrate/inhibitor/inducer | No dose change | | Pharmacokinetic (P-gp) | None | Evolocumab is not a P-gp substrate/inhibitor/inducer | No dose change | | Pharmacodynamic (bleeding) | Theoretical, not observed | Very low LDL-C plus anticoagulation | Monitor per standard of care | | Pharmacodynamic (platelet) | None | PCSK9 inhibition does not affect platelets | No action needed |